CERo Therapeutics (CERO) Competitors

CERo Therapeutics (NASDAQ:CERO) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Does the media prefer CERO or MBRX?

In the previous week, Moleculin Biotech had 10 more articles in the media than CERo Therapeutics. MarketBeat recorded 15 mentions for Moleculin Biotech and 5 mentions for CERo Therapeutics. Moleculin Biotech's average media sentiment score of 0.68 beat CERo Therapeutics' score of 0.06 indicating that Moleculin Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CERo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moleculin Biotech	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, CERO or MBRX?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$2.54M	N/A	N/A
Moleculin Biotech	N/A	N/A	-$29.77M	N/A	N/A

Which has more volatility & risk, CERO or MBRX?

CERo Therapeutics has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500.

Do insiders & institutionals believe in CERO or MBRX?

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 18.0% of CERo Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Moleculin Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer CERO or MBRX?

Moleculin Biotech received 231 more outperform votes than CERo Therapeutics when rated by MarketBeat users.

Company	Underperform	Outperform
CERo Therapeutics	N/A	N/A
Moleculin Biotech	Outperform Votes 231 49.36%	Underperform Votes 237 50.64%

Is CERO or MBRX more profitable?

CERo Therapeutics' return on equity of 0.00% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-108.43%
Moleculin Biotech	N/A	-157.44%	-97.16%

Do analysts rate CERO or MBRX?

Moleculin Biotech has a consensus price target of $17.33, suggesting a potential upside of 1,707.25%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than CERo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Moleculin Biotech	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Moleculin Biotech beats CERo Therapeutics on 8 of the 12 factors compared between the two stocks.